ArticleCureus2026
Development of a New Tablet-Based Cognitive Screening Test for Community-Dwelling Older Adults.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly detection of cognitive decline in community-dwelling older adults requires accessible, automated screening tools that minimize the burden on healthcare personnel. To address this, we developed a novel, tablet-based cognitive screening tool that might be administered within the Specific Health Checkups (SHC) framework and used by
resultsA total of 70 participants were enrolled (34 males, 36 females; mean age: 80.9 ± 6.5 years; mean education years: 11.6 ± 2.2 years). A strong positive correlation was observed between the total scores of the CANDIDE and the MMSE-J (r = 0.721, p < 0.001). Based on linear regression, the standard MMSE-J cutoff score of 24 corresponded to a CANDIDE score of 21.2.
conclusionThe CANDIDE might be a feasible tool for screening of cognitive decline in individuals aged 40-74. Further investigation is warranted to validate its clinical utility and cost-effectiveness within the annual SHC framework, as well as its efficacy as an objective assessment tool for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.